Table 2 Baseline Characteristics of the included studies
Study ID | Study arms | Sample | Age, years, M ± SD | Sex, male (%) | Body mass index, Kg/m2, M ± SD | Married, n (%) | Employed, n (%) | Education (≥ 12 y), n (%) | Income (< 30,000 $/y), n (%) | NYHA classification, n (%) | Most common comorbidities, n (%) | Antidepressant medication use at admission, n (%) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
I | II | III | IV | Previous myocardial infarctions | Diabetes | Prior stroke | COPD | Hypertension | History of renal disease | History of atrial fibrillation | |||||||||||
Cajanding et al. 2016 | CBT | 52 | Reported as age groups | 33 (69%) | NR | 36 (75%) | NR | 15 (31%) | NR | 7 (15%) | 20 (42%) | 19 (40%) | 2 (4%) | 23 (48%) | 9 (17.3%) | 6 (11.5%) | 4 (7.7%) | 19 (36.5%) | NR | NR | NR |
Control | 48 | 34 (65%) | NR | 39 (75%) | NR | 16 (31%) | NR | 5 (10%) | 23 (44%) | 21 (40%) | 3 (6%) | 19 (36.5%) | 8 (15.4%) | 4 (7.7%) | 4 (7.7%) | 18 (34.6%) | NR | NR | NR | ||
Dekker et al. 2012 | CBT | 21 | 68 ± 10 | 11 (52%) | 28.2 ± 6.4 | 14 (66.7%) | 2 (10%) | 5 (24%) | NR | 0 (0%) | 6 (29%) | 15 (71%) | 0 (0%) | 8 (38%) | 9 (43%) | 4 (19%) | 12 (57%) | NR | 9 (43%) | 8 (38%) | 7 (33%) |
Control | 21 | 64 ± 12 | 12 (57%) | 33.8 ± 9.7 | 10 (48%) | 1 (5%) | 9 (45%) | NR | 0 (0%) | 2 (10%) | 16 (76%) | 3 (14%) | 9 (43%) | 10 (48%) | 4 (19%) | 5 (25%) | NR | 7 (33%) | 11 (52%) | 8 (38%) | |
Freedland et al. 2015 | CBT | 79 | 56.2 ± 11.5 | 39 (49.4%) | 34.7 ± 7.9 | 34 (43.0%) | 17 (21.5%) | 67 (84.8%) | 34 (49.3%) | 46 (58.2%) | 33 (41.8%) | 0 (0%) | 25 (31.7%) | 27 (34.2%) | NR | 11 (13.9%) | 54 (68.4%) | NR | 26 (32.9%) | 26 (32.9%) | |
Control | 79 | 55.5 ± 10.9 | 46 (58.2%) | 32.6 ± 7.8 | 40 (50.6%) | 17 (21.5%) | 68 (86.1%) | 32 (48.5%) | 45 (57.0%) | 34 (43.0%) | 0 (0%) | 24 (31.6%) | 33 (41.8%) | NR | 18 (22.8%) | 59 (74.7%) | NR | 30 (38.0%) | 26 (32.9%) | ||
Freedland et al. 2022 | CBT | 69 | 58.0 ± 11.5 | 36 (52.2%) | NR | 26 (37.7%) | NR | 17 (24.6%) | 35 (50.7%) | 44 (63.8%) | NR | NR | 28 (40.6%) | 28 (40.6%) | NR | 14 (20.3%) | 56 (81.2%) | 21 (30.4%) | 23 (33.3%) | 31 (44.9%) | |
Control | 70 | 58.3 ± 12.2 | 35 (50%) | NR | 27 (38.6%) | NR | 14 (20.0%) | 30 (42.9%) | 47 (67.1%) | NR | NR | 21 (30.0%) | 35 (50.0%) | NR | 21 (30.0%) | 61 (87.1%) | 12 (17.1%) | 28 (40.0%) | 31 (44.3%) | ||
Hwang et al. 2022 | CBT | 14 | 66.54 ± 11.33 | 9 (64.3%) | NR | 11 (78.6%) | 3 (21.4%) | 5 (35.7%) | 3 (21.4%) * | 0 (0.0%) | 6 (42.9%) | 6 (42.9%) | 2 (14.3%) | NR | NR | NR | NR | NR | NR | NR | NR |
Control | 12 | 67.41 ± 17.14 | 3 (25%) | NR | 8 (66.7%) | 1 (8.3%) | 9 (75.0%) | 3 (25.0%) * | 0 (0.0%) | 6 (50%) | 6 (50%) | 0 (0.0%) | NR | NR | NR | NR | NR | NR | NR | NR | |
Khayati et al. 2020 | CBT | 40 | 53.08 ± 10.11 | 22 (55%) | NR | 36 (90%) | 14 (35%) | 10 (25%) | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
Control | 40 | 51.63 ± 8.33 | 24 (60%) | NR | 35 (87.5%) | 13 (32.5%) | 12 (30%) | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |
Moradi et al. 2022 | CBT | 33 | 58.70 ± 7.91 | 18 (54.5%) | NR | 22 (66.7%) | 4 (12.1%) | 5 (15.2%) | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
Control | 33 | 58.24 ± 8.32 | 20 (60.6%) | NR | 25 (75.8%) | 6 (18.1%) | 2 (6.1%) | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | |